RxDoctor Payments Data

Elizabeth Phung-Hart, DO

Internal Medicine · Las Vegas, NVNPI 1649681636

Payments from drug & device makers

$9,848in general payments, 2019–2025

Across 415 payments — averaging $23.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$945
  • Bayer$910
  • Novartis$837
  • Boehringer Ingelheim$770
  • Novo Nordisk$587
  • Johnson & Johnson$485
  • plus $5K from 39 others

What the payments were for

  • Grants$160%
  • Food & beverage$9,37795%
  • Education$3273%
  • Other$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,848 in reported general payments places this provider in the 90th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$459,718
Medicare patients
668
Services billed
5,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin106$116,132
EliquisApixaban94$104,678
FarxigaDapagliflozin Propanediol45$44,927
XareltoRivaroxaban29$34,510
OzempicSemaglutide32$28,185
EntrestoSacubitril/Valsartan15$12,527
Repatha SureclickEvolocumab17$11,242
BrilintaTicagrelor17$10,695
VascepaIcosapent Ethyl17$5,538
Icosapent Ethyl22$5,051
Metoprolol Succinate176$3,194
Amiodarone Hcl33$2,638
Atorvastatin Calcium201$2,060
Ezetimibe62$1,874
Ranolazine ErRanolazine12$1,871

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$770$116,132106 claims
PfizerEliquis$387$104,67894 claims
AstraZenecaFarxiga, Brilinta$945$55,62262 claims
Johnson & JohnsonXarelto$485$34,51029 claims
Novo NordiskOzempic$587$28,18532 claims
NovartisEntresto$837$12,52715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →